Sensitive Immunosensor for Cancer Biomarker Based on Dual Signal Amplification Strategy of Graphene Sheets and Multienzyme Functionalized Carbon Nanospheres

Dan Du,‡‡ Zhexiang Zou,‡ Yongsoon Shin,‡ Jun Wang,‡ Hong Wu,‡ Mark H. Engelhard,‡ Jun Liu,‡ Ilhan A. Aksay,§ and Yuehe Lin*,‡

Key Laboratory of Pesticide and Chemical Biology of Ministry of Education, College of Chemistry, Central China Normal University, Wuhan 430079, PR China, Pacific Northwest National Laboratory, Richland, Washington 99352, and Department of Chemical Engineering, Princeton University, Princeton, New Jersey 08544

A novel electrochemical immunosensor for sensitive detection of cancer biomarker α-fetoprotein (AFP) is described that uses a graphene sheet sensor platform and functionalized carbon nanospheres (CNSs) labeled with horseradish peroxidase-secondary antibodies (HRP-Ab2). Greatly enhanced sensitivity for the cancer biomarker is based on a dual signal amplification strategy: first, the synthesized CNSs yielded a homogeneous and narrow size distribution, which allowed several binding events of HRP-Ab2 on each nanosphere. Enhanced sensitivity was achieved by introducing the multibioconjugates of HRP-Ab2-CNSs onto the electrode surface through “sandwich” immunoreactions. Second, functionalized graphene sheets used for the biosensor platform increased the surface area to capture a large amount of primary antibodies (Ab1), thus amplifying the detection response. On the basis of the dual signal amplification strategy of graphene sheets and the multienzyme labeling, the developed immunosensor showed a 7-fold increase in detection signal compared to the immunosensor without graphene modification and CNSs labeling. The proposed method could respond to 0.02 ng mL⁻¹ AFP with a linear calibration range from 0.05 to 6 ng mL⁻¹. This amplification strategy is a promising platform for clinical screening of cancer biomarkers and point-of-care diagnostics.

Sensitive detection of disease-related proteins is critical to many areas of modern biochemical and biomedical research. In particular, the clinical measurement of cancer biomarkers shows great promise for early disease detection and highly reliable predictions. It also offers opportunities for understanding fundamental biological processes involved in disease progression and monitoring patient responses to therapy methods. Conventional immunoassay methods, including the enzyme-linked immunosorbent assay (ELISA), radioimmunoassay, fluorescence immunoassay, chemiluminescence immunoassay, electrophotonic immunoassay, mass spectrometric immunoassay, and immune-polymerase chain reaction (PCR) assay allow reliable predictions. However, the increasing demand for early and ultrasensitive screening of cancer biomarkers is pushing the enhancement of detection sensitivity by signal amplification or novel detection technologies. For point-of-care applications, the sensors need to be inexpensive, operationally simple, and highly sensitive to address both levels of the biomarkers in normal and cancer patient sera.

The electrochemical immunoassay combined with nanostructured materials opens new horizons for highly sensitive detection of biomarkers because of the nanoparticle-based signal amplification platform. To date, three approaches have been developed for signal amplification of nanoparticle-based electrochemical biosensors: (1) Metal and semiconductor nanoparticles are directly used as electroactive labels to amplify the electrochemical signal; (2) Metal and semiconductor nanoparticles are conjugated to primary antibodies and used as labels; and (3) Metal and semiconductor nanoparticles are functionalized with a specific recognitive ligand to capture specific targets. In this paper, we describe a novel surface-enhanced electrochemical platform for clinical screening of cancer biomarkers and point-of-care diagnostics.
response of DNA or proteins.\textsuperscript{24}–\textsuperscript{28} (2) Nanoparticles are used as carriers to load a large amount of electroactive species, such as ferrocene, to amplify the detection of biomolecules.\textsuperscript{25}–\textsuperscript{29} Our group has reported this novel strategy using poly (guanine)-functionalized silica nanoparticles to introduce a large amount of guanine residues on the electrode. Ru(bpy)-induced catalytic oxidation of guanine resulted in great enhancement of the anodic current.\textsuperscript{25}–\textsuperscript{27} (3) Enzyme-functionalized nanoparticles are used as the label to enhance detection sensitivity, which is obtained by increasing the enzyme loading toward a sandwich immunological reaction event.\textsuperscript{30}–\textsuperscript{33} Rusling’s group has achieved greatly enhanced sensitivity using bioconjugates featuring horseradish peroxidase (HRP) labels and secondary antibodies linked to enhanced sensitivity using bioconjugates featuring horseradish peroxidase (HRP) labels and secondary antibodies linked to carbon nanotubes (CNTs) for immunodetection of the prostate specific antigen.\textsuperscript{30} Also, they developed an ultrasensitive immunosensor for a cancer biomarker by synthesizing magnetic bioconjugate particles containing 7500 HRP labels along with detection antibodies.\textsuperscript{31} Recently, Liu and co-workers reported HRP-functionalized silica nanoparticles as a label for detecting ß-fetoprotein (AFP).\textsuperscript{32} The improved particle synthesis using a “seed-particle growth” route yielded particles of narrow size distribution, which allowed consistent loading of HRP and AFP antibodies to enhance detection sensitivity.

Carbon nanomaterials have attracted considerable attention in electrochemical biosensors because of their extraordinary physical properties and remarkable conductivities.\textsuperscript{34,35} While CNTs have been widely used as labeling particles in immunoassays with excellent sensitivity, problems that need to be overcome include nanotube heterogeneity and purity. Recently, porous carbon nanospheres (CNSs) have also displayed unique advantages owing to the tunability of particle size and shape as well as the resident porosity that promotes diffusion of guest molecules through interconnected micropores.\textsuperscript{36,37} A “green” synthetic approach has been developed that involves the transformation of sugars into homogeneous and stable colloidal CNSs, which are hydrophilic.\textsuperscript{38,39} Such surface-functionalized CNSs and porous structures are potentially beneficial for labeling.

For carbon electrodes, the electrocatalytic properties strongly depend on their microstructure and surface chemistry. Recently, graphene has emerged as an interesting material because of its unusual electronic properties and large accessible surface area.\textsuperscript{40,41} Biocompatible graphene sheets as a sensor platform not only present an abundant domain for biomolecular binding but also play a role of fast electron-transfer kinetics and further signal amplification in electrochemical detection.\textsuperscript{42}–\textsuperscript{44} For example, a novel electrode system using reduced graphene oxide as a biosensing platform has been proposed. Graphene sheets showed favorable electrochemical activity to several electroactive compounds.\textsuperscript{45} In addition, graphene electrodes exhibited a superior biosensing performance over single-walled carbon nanotubes toward dopamine detection in the presence of common interfering agents, such as ascorbic acid and serotonin.\textsuperscript{46}

In this paper, we report an electrochemical immunosensor for sensitive detection of biomarkers based on a dual amplification mechanism resulting from multienzyme-antibody functionalized CNSs and functionalized graphene sheets as the sensor platform. The synthesized colloidal CNSs from fructose under hydrothermal treatment were employed as a carrier for HRP-secondary antibody conjugates, which allows consistent loading of HRP and AFP antibodies to enhance detection sensitivity. The proposed immunosensor shows potential applications in clinical screening of cancer biomarkers and point-of-care diagnostics.

**EXPERIMENTAL SECTION**

**Reagents and Materials.** AFP, mouse monoclonal antibody to AFP (anti-AFP, Ab1), and HRP-labeled mouse monoclonal antibody to AFP (HRP-anti-AFP, HRP-Ab2) were purchased from Abcam, Inc. Bovine serum albumin (BSA), Tween-20, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC), N-hydroxysuccinimide (NHS), 3,3′,5,5′-tetrathylbenzidine (TMB), chitosan, phosphate buffer saline (PBS), and 2-(N-morpholino)ethanesulfonic acid (MES) were acquired from Sigma/Aldrich. The other reagents were purchased from commercial sources and were used without further purification.

**Methods.** The determination of AFP was based on the inhibition of a catalytic reaction in electrochemical detection. For carbon electrodes, the electrocatalytic properties strongly depend on their microstructure and surface chemistry. Recently, graphene has emerged as an interesting material because of its unusual electronic properties and large accessible surface area.\textsuperscript{40,41} Biocompatible graphene sheets as a sensor platform not only present an abundant domain for biomolecular binding but also play a role of fast electron-transfer kinetics and further signal amplification in electrochemical detection.\textsuperscript{42}–\textsuperscript{44} For example, a novel electrode system using reduced graphene oxide as a biosensing platform has been proposed. Graphene sheets showed favorable electrochemical activity to several electroactive compounds.\textsuperscript{45} In addition, graphene electrodes exhibited a superior biosensing performance over single-walled carbon nanotubes toward dopamine detection in the presence of common interfering agents, such as ascorbic acid and serotonin.\textsuperscript{46}

**This in paper, we report an electrochemical immunosensor for sensitive detection of biomarkers based on a dual amplification mechanism resulting from multienzyme-antibody functionalized CNSs and functionalized graphene sheets as the sensor platform. The synthesized colloidal CNSs from fructose under hydrothermal treatment were employed as a carrier for HRP-secondary antibody conjugates, which allows consistent loading of HRP and AFP antibodies to enhance detection sensitivity. The proposed immunosensor shows potential applications in clinical screening of cancer biomarkers and point-of-care diagnostics.**
graphene used in our study was made by thermal exfoliation of graphite oxide,\textsuperscript{48} which starts with the chemical oxidation of graphite flakes to increase the \(c\)-axis spacing from 0.34 to 0.7 nm. The resulting graphite oxide was split apart through rapid thermal expansion to yield single but wrinkled graphene sheets functionalized with hydroxyl and carboxylic groups.\textsuperscript{43}

**Apparatus.** Electrochemical experiments, including cyclic voltammetry (CV) and square wave voltammetry (SWV), were performed with an electrochemical analyzer CHI 660A (CH Instruments, Austin, TX) connected to a personal computer. Disposable screen-printed carbon electrodes (SPCE) consisting of graphene sheets-chitosan modified working carbon electrodes (GS-CHI/SPCE), a carbon counter electrode, and an Ag/AgCl reference electrode were purchased from Alderon Biosciences, Inc. A sensor connector (Alderon Biosciences, Inc.) was used to connect the disposable SPCE to the CHI electrochemical analyzer. Dried carbon spheres were characterized by the use of field emission scanning electron microscopy (FE-SEM) JEOL-JSEM 633 F. X-ray photoelectron spectroscopy (XPS) measurements were taken with a Physical Electronics Quantum 2000 scanning microscope. This system uses a focused monochromatic aluminum Kx X-ray (1486.7 eV) source for excitation and a spherical section analyzer. A 100 W X-ray beam focused to a diameter of 100 μm was rastered over a 1.3 mm × 0.2 mm rectangle on the sample. The high-energy resolution data were collected using a pass energy of 46.95 eV. These conditions produced a full-width half-maximum of 0.98 eV for the Ag 3d\(\text{5/2}\) line. The binding-energy scale was calibrated using Cu 2p3/2 at 932.62 ± 0.05 eV and Au 4f at 83.96 ± 0.05 eV.

**Synthesis of Colloidal CNSs.** Colloidal CNSs was synthesized from fructose in closed systems under hydrothermal conditions and characterized by 13C solid-state nuclear magnetic resonance (NMR), Fourier transform-infrared (FT-IR) spectra, and electron imaging studies (SEM and transmission electron microscopy [TEM]).\textsuperscript{49,50} Briefly, in situ Raman spectra were taken with a Physical Electronics Quantum 2000 scanning microscope. To determine the amount of active HRP in the dispersion, the mixture was reacted with HRP substrate TMB. The reaction product was read at 650 nm. This was compared to a standard curve constructed with pure HRP by an enzyme activity experiment. The concentration of active Ab2-HRP in the stock HRP-Ab2-CNSs dispersion was determined to be 3.07 μg/mL.

**Fabrication of Functionalized Graphene Sheets Immunosensor.** Functional graphene sheets (FGSs) were prepared through a thermal expansion process. The detailed synthesis process and the characterization of the FGSs used in this work have been reported elsewhere.\textsuperscript{48,51} The suspension of graphene was first prepared by dispersing 0.5 mg of graphene in 1 mL of 0.2% chitosan solution (pH 5.2). The mixture was sonicated for 1 h to obtain a homogeneous dispersion. Then a 5 μL suspension was cast on a pretreated working carbon electrode and dried at room temperature. To attach primary AFP antibodies, 10 μL of freshly prepared 400 mM EDC and 100 mM NHS were placed onto the GS-CHI/SPCE and washed off after 30 min. This was immediately followed by a 2 h incubation at 37 °C with 20 μL of 0.5 mg/mL primary AFP antibodies (Ab1) in pH 7.4 PBS. After washing with 0.05% Tween-20 and PBS buffer, the Ab1/GS-CHI/SPCE was incubated in 3% BSA and PBS solution at 37 °C for 1 h.
to block excess active groups and nonspecific binding sites on the surface. The electrode was then washed with 0.05% Tween-20 and PBS buffer before use.

**Immunoassay Procedure for Detection of AFP.** A sandwich immunoassay was used for determination of AFP. (1) The immunosensor, Ab1/GS-CHI/SPCE, was incubated with 10 µL of a different concentration of AFP standard antigen at 37 °C for 60 min, followed by washing with 0.05% Tween-20 and PBS buffer. (2) Next, the electrode (AFP/Ab1/GS-CHI/SPCE) was incubated with 10 µL of HRP-Ab2-CNSs dispersion at 37 °C for 40 min, followed by washing with 0.05% Tween-20 and PBS buffer to remove the nonspecific adsorption of CNSs. (3) The immunosensor was then detected in 2 mM o-phenylenediamine (o-PD) and 4 mM H₂O₂.

**RESULTS AND DISCUSSION**

**Dual Signal Amplification Strategy Using Graphene and HRP-anti-AFP-CNSs.** Scheme 2 displayed electrochemical immunoassay steps, including a traditional labeled protocol (A) and a signal amplification strategy using multienzyme-antibody labels (B) on graphene sheets. Herein, we pursued graphene sheets and a multienzyme-antibody labeling strategy to enhance sensitivity. The secondary antibody is enzyme-labeled conjugate (HRP-Ab2), which serves as a signaling antibody in sandwiched immunodetection. To achieve an amplification signal, we use CNSs as a carrier to load a large number of HRP-Ab2, which results in loading more enzymes in the sandwiched immunoreactions. A greatly amplified response was achieved by the use of multibioconjugates of HRP-Ab2-CNSs to replace HRP-Ab2. The graphene sheets used as a sensor platform increased the surface area to capture a large amount of primary antibodies, thus amplifying the detection signal.

**SEM Images of Synthesized CNSs.** Figure 1 shows SEM images of the final product of CNSs. They demonstrate a homogeneous distribution with an average size of 400 nm in diameter (Figure 1A). Detailed magnified images of CNSs (Figure 1B) appeared smooth with a small porous structure. These monodispersed CNSs were vital for loading HRP-Ab1 on each nanosphere, which would influence the sensitivity and analytical performance of the resulting immunosensor.

**XPS Analysis of Functionalized CNSs and HRP-Ab2-CNSs.** Figure 2 displays XPS spectra of the original synthesized CNSs, acid treated CNSs, and HRP-Ab2-CNSs conjugate. One can see that both the original synthesized CNSs (curve a) and acid treated CNSs (curve b) showed the binding energy of the core electrons for the C₁s line at 284.8 eV from the C–H groups (Figure 2A). After treating with concentrated acid, the functionalization of the CNSs were confirmed by the significantly increased signal in the peak at 288.6 eV (curve b), which was attributed to the COOH unit. These data indicated that successful acid treatment of CNSs has introduced more carboxylic groups on the surface.

function of antibodies, indicating successful modification of the detection signal more than the traditionally labeled HRP-Ab2. The multienzyme-antibody labeling strategy enhanced the SPCE (curve d) increased significantly. It is not surprising that the electrocatalytic current at HRP-Ab2-CNSs/AFP/Ab1/GS-CHI/SPCE (curve d) increased because the resulting HRP-Ab2/AFP/Ab1/GS-CHI/SPCE displayed a slight increase in catalytic reduction current (curve c) compared with HRP-Ab2/AFP/Ab1/GS-CHI/SPCE (curve b). The N\textsubscript{i}\textsubscript{a} core level spectra showed a typical binding energy of the amide nitrogen atoms (HN\textsubscript{–}C=O) coming from the function of antibodies, indicating successful modification of CNSs to form the HRP-Ab2-CNSs conjugate.

**Electrochemical Behaviors of the Immunosensors.** As shown in Figure 3, the cyclic voltammogram of Ab1/GS-CHI/SPCE did not show any detectable signal in pH 7.4 PBS (curve a). Upon adding 2 mM o-PD and 4 mM H\textsubscript{2}O\textsubscript{2} to the PBS buffer, the cyclic voltammogram of Ab1/GS-CHI/SPCE exhibited a pair of stable and well-defined redox peaks at −0.125 and −0.152 V (curve b), which correspond to the electrochemical response of o-PD. When incubating the immunosensor with 2 ng mL\textsuperscript{−1} AFP, no obvious change in signal was observed (data not shown), but after incubating with the HRP-Ab2 solution, the resulting HRP-Ab2/AFP/Ab1/GS-CHI/SPCE displayed a slight increase in catalytic reduction current (curve c) because of HRP on the electrode surface. However, when replacing HRP-Ab2 with HRP-Ab2-CNSs as a detection antibody, the electrocatalytic current at HRP-Ab2-CNSs/Ab1/GS-CHI/SPCE (curve d) increased significantly. It is not surprising that the multienzyme-antibody labeling strategy enhanced the detection signal more than the traditionally labeled HRP-Ab2.

The signal amplification was also confirmed by SWV measurement. As shown in Figure 4, a 3.5-fold increase in the catalytic current was observed at HRP-Ab2-CNSs/AFP/Ab1/GS-CHI/SPCE (curve a) compared with HRP-Ab2/AFP/Ab1/GS-CHI/SPCE (curve b) since HRP-Ab2-CNSs as a detection antibody could introduce more HRP on the electrode surface. This phenomenon could also be seen even with oxidized CHI without graphene modification. The catalytic current obtained from HRP-Ab2-CNSs/AFP/Ab1/GS-CHI/SPCE was 3.0-fold higher than that from HRP-Ab2 (curve d). The achieved amplification was mainly ascribed to the excessive enzyme present in the CNSs label when HRP-Ab2-CNSs was used as a detection antibody. Furthermore, we explored the role of graphene sheets as a sensor platform. Compared to AFP/Ab1/CHI/SPCE and AFP/Ab1/GS-CHI/SPCE, the catalytic current increased from 3.13 µA (curve c) to 7.87 µA (curve a) when HRP-Ab2-CNSs was used as a detection antibody. Also, the responses increased from 1.18 µA at AFP/Ab1/CHI/SPCE (curve d) to 2.66 µA at AFP/Ab1/GS-CHI/SPCE (curve b) when traditionally labeled HRP-Ab2 was used. These data illustrated that although CHI/SPCE could also specifically capture Ab1, much lower peak currents and slight positively shifted potentials were observed compared to those at GS-CHI/SPCE. The presence of graphene not only obviously increased the surface area to capture more antibodies on the electrode surface but also accelerated electron transfer. On the basis of the dual amplification of graphene sheets and HRP-Ab2-CNSs, the catalytic current at HRP-Ab2-CNSs/AFP/Ab1/GS-CHI/SPCE enhanced about 7-fold in comparison with that at GS-CHI/SPCE without graphene modification and CNSs labeling.

A series of control experiments were conducted in PBS containing o-PD and H\textsubscript{2}O\textsubscript{2} by SWV measurements. As shown in Figure 5, both the Ab1/CHI/SPCE (a) and Ab1/GS-CHI/SPCE (b) presented small signals. A slight increase of catalytic currents was obtained when the Ab1/GS-CHI/SPCE was directly exposed to HRP-Ab2 (c) or HRP-Ab2-CNSs (e) without preincubation in AFP. The responses increased from 1.18 µA to 2.66 µA when incubating with AFP/Ab1/GS-CHI/SPCE (curve b) when traditionally labeled HRP-Ab2 was used. These data illustrated that although CHI/SPCE could also specifically capture Ab1, much lower peak currents and slight positively shifted potentials were observed compared to those at GS-CHI/SPCE. The presence of graphene not only obviously increased the surface area to capture more antibodies on the electrode surface but also accelerated electron transfer. On the basis of the dual amplification of graphene sheets and HRP-Ab2-CNSs, the catalytic current at HRP-Ab2-CNSs/AFP/Ab1/GS-CHI/SPCE enhanced about 7-fold in comparison with that at HRP-Ab2/AFP/Ab1/CHI/SPCE without graphene modification and CNSs labeling.

![Figure 3](image1.png)  
**Figure 3.** Cyclic voltammograms of Ab1/GS-CHI/SPCE in pH 7.4 PBS (a) and Ab1/GS-CHI/SPCE (b) and HRP-Ab2/AFP/Ab1/GS-CHI/SPCE (c) and HRP-Ab2-CNSs/AFP/Ab1/GS-CHI/SPCE (d) in PBS containing 2 mM o-PD and 4 mM H\textsubscript{2}O\textsubscript{2}. Two ng mL\textsuperscript{−1} AFP was used during the incubation process at 37 °C for 1 h.

![Figure 4](image2.png)  
**Figure 4.** Square wave voltammograms of HRP-Ab2-CNSs/AFP/Ab1/GS-CHI/SPCE (a), HRP-Ab2/Ab1/Ab1/GS-CHI/SPCE (b), HRP-Ab2/AFP/Ab1/GS-CHI/SPCE (c), and HRP-Ab2/Ab1/GS-CHI/SPCE (d) in pH 7.4 PBS containing 2 mM o-PD and 4 mM H\textsubscript{2}O\textsubscript{2}. Two nanograms mL\textsuperscript{−1} AFP was used during the incubation process at 37 °C for 1 h.

![Figure 5](image3.png)  
**Figure 5.** Amperometric responses of Ab1/CHI/SPCE (a), Ab1/GS-CHI/SPCE (b), HRP-Ab2/Ab1/Ab1/GS-CHI/SPCE (c), HRP-Ab2/AFP/Ab1/GS-CHI/SPCE (d), HRP-Ab2-CNSs/Ab1/GS-CHI/SPCE (e), and HRP-Ab2-CNSs/AFP/Ab1/GS-CHI/SPCE (f) in pH 7.4 PBS containing 2 mM o-PD and 4 mM H\textsubscript{2}O\textsubscript{2}.

After increasing the incubation time with 2 ng mL\(^{-1}\) specifically recognizing HRP-Ab2-CNSs on the electrode surface.

was important parameter for both capturing AFP antigens and suggested a Michaelis-Menten’s mechanism in the electrochemical enzyme-catalyzed analysis. Therefore, the optimal incubation time for the first and second immunoassay incubation step, the SWV response in-creased and reached a plateau at 40 min (curve b in Figure 6A). A long time incubation could result in a large nonspecific signal. Therefore, the optimal incubation time for the first and second immunoreactions was 60 and 40 min, respectively.

The performance of the electrochemical enzyme-catalyzed analysis was related to the concentration of o-PD and H\(_2\)O\(_2\) in the measuring system.\(^{54}\) As shown in Figure 6B, the SWV peak current of the resulting HRP-Ab2-CNSs/AFP/Ab1/GS-CHI/SPCE increased with the increasing concentrations of o-PD (curve a) and H\(_2\)O\(_2\) (curve b) and maintained the maximum value at higher concentrations. Afterward, the enzymatic reaction rate depended on the amount of the labeled HRP. This result suggested a Michaelis–Menten’s mechanism in the electrochemical enzyme-catalyzed analysis. Therefore, the optimal o-PD and H\(_2\)O\(_2\) concentrations were 2 mM and 4 mM, respectively.

Electrochemical Detection. Under optimal conditions, the electrocatalytic currents of the HRP-Ab2-CNSs/AFP/Ab1/GS-CHI/SPCE increased with the increase of AFP concentrations larger than that from HRP-Ab2 (d/c), thus amplifying the detection signal.

Optimization of Detection Conditions. The incubation time was an important parameter for both capturing AFP antigens and specifically recognizing HRP-Ab2-CNSs on the electrode surface. After increasing the incubation time with 2 ng mL\(^{-1}\) AFP, the SWV peak current at the HRP-Ab2-CNSs/AFP/Ab1/GS-CHI/SPCE increased and tended to a steady value after 60 min (curve a in Figure 6A), indicating a tendency to thoroughly capture AFP antigens on the electrode surface. After incubating the AFP/Ab1/GS-CHI/SPCE with HRP-Ab2-CNSs used in the second immunoassay incubation step, the SWV response increased and reached a plateau at 40 min (curve b in Figure 6A). A long time incubation could result in a large nonspecific signal. Therefore, the optimal incubation time for the first and second immunoreactions was 60 and 40 min, respectively.

The reproducibility of the proposed immunosensor for AFP detection, the immunosensor was incubated in 2 ng mL\(^{-1}\) AFP containing a different interfering agent, such as carcinoembryonic antigen (CEA), carcinoma antigen 125 (CA125), and a prostate-specific antigen (PSA). No remarkable change of current was observed in comparison with the result obtained in the presence of AFP only, indicating good selectivity of the proposed AFP immunosensor.

Evaluation of the Immunosensor. The accuracy of the quantification of AFP was tested by adding different amounts of AFP into serum samples, and the results were compared with ELISA. The results are summarized in Table 1. The recoveries from these two methods ranged from 97.1 to 104.6% and 97.4 to 103.8%, respectively. The relative deviation was lower than 3.0%, indicating acceptable accuracy.

The reproducibility of the proposed immunosensor was evaluated by intra- and interassay coefficients of variation (CVs). The relative deviation was lower than 3.0%.

![Figure 6](image)

(A) Dependence of SWV peak currents on the incubation time of AFP (a) and HRP-Ab2-CNSs (b) at Ab1/GS-CHI/SPCE. (B) Dependence of SWV peak currents on concentrations of o-PD (a) and H\(_2\)O\(_2\) (b).

![Figure 7](image)

SWV curves of HRP-Ab2-CNSs/AFP/Ab1/GS-CHI/SPCE after incubation with 0 (a), 0.05 (b), 0.1 (c), 0.2 (d), 0.5 (e), 1 (f), 2 (g), 4 (h), 6 (i), and 10 (j) ng mL\(^{-1}\) AFP in pH 7.4 PBS containing 2 mM o-PD and 4 mM H\(_2\)O\(_2\). Inset: plot of the electrocatalytic currents of the immunosensor vs the concentrations of AFP.

Table 1. Recovery Studies of AFP in Serum Samples with Two Methods

<table>
<thead>
<tr>
<th>sample</th>
<th>added (ng mL(^{-1}))</th>
<th>found (ng mL(^{-1}))</th>
<th>immunosensor recoveries (%)</th>
<th>ELISA recoveries (%)</th>
<th>relative deviation (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.5</td>
<td>0.523</td>
<td>104.6</td>
<td>103.8</td>
<td>0.77</td>
</tr>
<tr>
<td>2</td>
<td>1.0</td>
<td>0.971</td>
<td>97.1</td>
<td>97.4</td>
<td>−0.31</td>
</tr>
<tr>
<td>3</td>
<td>2.0</td>
<td>1.986</td>
<td>99.3</td>
<td>101.1</td>
<td>−1.73</td>
</tr>
<tr>
<td>4</td>
<td>3.0</td>
<td>2.933</td>
<td>97.8</td>
<td>100.6</td>
<td>−2.78</td>
</tr>
</tbody>
</table>


intra-assay precision of the analytical method was evaluated by analyzing one immunosensor for six replicate determinations. The CVs of the intra-assay were 3.5% and 5.9% at 0.1 and 2.0 ng mL\(^{-1}\) AFP, respectively. Similarly, the interassay CVs on six immunosensors were 4.3% and 5.5% at 0.1 and 2.0 ng mL\(^{-1}\) AFP, respectively. These results indicated acceptable reproducibility and precision of the proposed immunosensor.

**CONCLUSIONS**

In this work, we have successfully developed a highly sensitive and selective immunosensor for detecting cancer biomarkers and demonstrated this signal amplification procedure. The greatly enhanced sensitivity relies upon a dual signal-amplification scheme: (1) CNSs as the enzyme-loading carrier can load many enzyme molecules on each CNSs. The labeling protocol allows multiple signals per binding event provided by the use of HRP-Ab2-CNSs in place of conventional HRP-Ab2, and (2) graphene sheets can provide a high density of primary antibodies because of their high surface area. The resulting immunosensor possesses high sensitivity, good reproducibility, and cost-effective analytical performance. We anticipate that this method can be expanded readily for detecting other relevant biomarkers and has the potential for reliable point-of-care diagnostics of cancer and other diseases.

**ACKNOWLEDGMENT**

The work was done at Pacific Northwest National Laboratory (PNNL) and was supported partially by Grant U54 ES16015 from the National Institute of Environmental Health Sciences, the National Institutes of Health, and a PNNL Laboratory Directed Research and Development project. This work was also supported partially by the National Natural Science Foundation of China (20705010). PNNL is operated for the U.S. Department of Energy (DOE) by Battelle under Contract DE-AC05-76RL01830. The characterization was performed using EMSL, a national scientific user facility sponsored by the Department of Energy’s Office of Biological and Environmental Research and located at Pacific Northwest National Laboratory. I.A.A. acknowledges support from ARO/MURI under Grant Number W911NF-09-1-0476 and Directed Technologies.

Received for review January 7, 2010. Accepted February 17, 2010.

AC100036P